Bill Ackman's hedge fund firm Pershing Square Capital Management is out with its 2016 annual report.
Pershing Square lost 13.5% net in 2016. The bulk of this loss was attributed to its previous position in Valeant Pharmaceuticals (VRX).
Ackman writes about why they
"If the stock price had increased even very substantially from here, the impact on our overall performance would have been modest, and would not compensate us for the human resources and substantial mindshare that this investment had and would have continued to...